UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 or 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2019
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrant’s name into English)
4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director Dealing
London, April 30, 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 29 April 2019, Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma, purchased 6000 American Depositary Shares (ADSs) at a total price of USD5.887 per ADS.
In addition, Richard Jones, Chief Financial Officer of Mereo BioPharma, purchased 2025 American Depositary Shares (ADSs) at a price of USD6.04 per ADS.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
| 1 | Details of the person discharging managerial responsibilities | |
| a) | Name | Denise Scots-Knight |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Mereo BioPharma Group plc |
| b) | LEI | 213800U8JQHIJOS5AS09 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs) |
| b) | Nature of the transaction | PURCHASE |
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
|
USD5.87
USD5.90 |
3000
3000 |
||||
| d) | Aggregated information: volume, Price |
Aggregated volume: 6000
Aggregated price: USD5.887 |
| e) | Date of the transaction | 2019-04-29 |
| f) | Place of the transaction | XNMS |
| 1 | Details of the person discharging managerial responsibilities | |
| a) | Name | Richard Jones |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Mereo BioPharma Group plc |
| b) | LEI | 213800U8JQHIJOS5AS09 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | ADS |
| b) | Nature of the transaction | Purchase |
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
|
USD6.04 |
2025 |
||||
| d) | Aggregated information: volume, Price |
Aggregated volume: 2025
Aggregated price: USD6.04 |
| e) | Date of the transaction | 2019-04-29 |
| f) | Place of the transaction | XNMS |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: April 30, 2019
| MEREO BIOPHARMA GROUP PLC | ||||
| By: | /s/ Charles Sermon | |||
| Name: | Charles Sermon | |||
| Title: | General Counsel | |||